Literature DB >> 34364926

Atypical antipsychotic drugs deregulate the cholesterol metabolism of macrophage-foam cells by activating NOX-ROS-PPARγ-CD36 signaling pathway.

Chia-Hui Chen1, Shr-Jeng Jim Leu2, Chiao-Po Hsu3, Ching-Chian Pan4, Song-Kun Shyue5, Tzong-Shyuan Lee6.   

Abstract

BACKGROUND: Clinical reports indicate that schizophrenia patients taking atypical antipsychotic drugs suffer from metabolism diseases including atherosclerosis. However, the mechanisms underlying the detrimental effect of atypical antipsychotic drugs on atherosclerosis remain to be explored.
METHODS: In this study, we used apolipoprotein E-deficient (apoe-/-) hyperlipidemic mice and apoe-/-cd36-/- mice to investigate the underlying mechanism of atypical antipsychotic drugs on atherosclerosis and macrophage-foam cells.
RESULTS: In vivo studies showed that genetic deletion of cd36 gene ablated the pro-atherogenic effect of olanzapine in apoe-/- mice. Moreover, in vitro studies revealed that genetic deletion or siRNA-mediated knockdown of cd36 or pharmacological inhibition of CD36 prevented atypical antipsychotic drugs-induced oxLDL accumulation in macrophages. Additionally, olanzapine and clozapine activated NADPH oxidase (NOX) to generate reactive oxygen species (ROS) which upregulated the activity of peroxisome proliferator-activated receptor γ (PPARγ) and subsequently elevated CD36 expression. Inhibition of NOX activity, ROS production or PPARγ activity suppressed CD36 expression and abolished the detrimental effects of olanzapine and clozapine on oxLDL accumulation in macrophages.
CONCLUSION: Collectively, our results suggest that atypical antipsychotic drugs exacerbate atherosclerosis and macrophage-foam cell formation by activating the NOX-ROS-PPARγ-CD36 pathway.
Copyright © 2021 The Author(s). Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Atherosclerosis; Atypical antipsychotic drug; CD36; Foam cell; Reactive oxygen species

Mesh:

Substances:

Year:  2021        PMID: 34364926     DOI: 10.1016/j.metabol.2021.154847

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  2 in total

Review 1.  Redox signaling at the crossroads of human health and disease.

Authors:  Jing Zuo; Zhe Zhang; Maochao Luo; Li Zhou; Edouard C Nice; Wei Zhang; Chuang Wang; Canhua Huang
Journal:  MedComm (2020)       Date:  2022-03-31

2.  Schizophrenia and Hospital Admissions for Cardiovascular Events in a Large Population: The APNA Study.

Authors:  Sara Guillen-Aguinaga; Antonio Brugos-Larumbe; Laura Guillen-Aguinaga; Felipe Ortuño; Francisco Guillen-Grima; Luis Forga; Ines Aguinaga-Ontoso
Journal:  J Cardiovasc Dev Dis       Date:  2022-01-13
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.